Zevra Therapeutics, Inc.
US ˙ NasdaqGS ˙ US4884452065

SecurityZVRA / Zevra Therapeutics, Inc.
InstitutionD. E. Shaw & Co., Inc.
ManagerDE Shaw
Latest Disclosed Ownership846,457 shares
Latest Disclosed Value $ 7,888,980
D. E. Shaw & Co., Inc. reports 2.00% decrease in ownership of ZVRA / Zevra Therapeutics, Inc.

On May 15, 2026 - D. E. Shaw & Co., Inc. filed a 13F-HR form disclosing ownership of 846,457 shares of Zevra Therapeutics, Inc. (US:ZVRA) valued at $7,888,979 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 863,746 shares of Zevra Therapeutics, Inc.. This represents a change in shares of -2.00% during the quarter. The current value of the position is $9,277,169 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ZEVRA THERAPEUTICS COM NEW 488445206 846,457 -17,289 -2.00 7,889 1.93 0.0047
2026-02-17 2025-12-31 13F ZEVRA THERAPEUTICS COM NEW 488445206 863,746 137,916 19.00 7,739 12.13 0.0042
2025-11-14 2025-09-30 13F ZEVRA THERAPEUTICS COM NEW 488445206 725,830 536,517 283.40 6,903 314.04 0.0039
2025-08-14 2025-06-30 13F ZEVRA THERAPEUTICS COM NEW 488445206 189,313 161,943 591.68 1,668 713.17 0.0012
2025-05-15 2025-03-31 13F ZEVRA THERAPEUTICS COM NEW 488445206 27,370 2,295 9.15 205 -1.91 0.0002
2025-02-14 2024-12-31 13F ZEVRA THERAPEUTICS COM NEW 488445206 25,075 25,075 209 0.0002
2022-08-15 2022-06-30 13F KEMPHARM COM NEW 488445206 0 -10,453 -100.00 0 -100.00
2022-05-16 2022-03-31 13F KEMPHARM COM NEW 488445206 10,453 -13,356 -56.10 53 -74.40 0.0000
2022-02-14 2021-12-31 13F KEMPHARM COM NEW 488445206 23,809 23,809 207 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.